Background. The Lithuanian Prostate Cancer Early Diagnosis Program (LPCEDP)

was launched in 2006. Our study aimed to evaluate the PSA testing offered by general practicians for prostate cancer screening as its results may differ from those reported in randomised screening studies. Materials and methods. In the LPCEDP, GPs offered a PSA (prostate-specific an-tigen) test for informed men aged 50–75 years. A PSA> 3 ng/ml was a cut-off limit for referral to urologist. The study group comprised men aged 50–75 years, diagnosed with prostate cancer in 2006–2009. The Lithuanian Cancer Registry data: age at diag-nosis, date of diagnosis, clinical stage. The state Patient Fund data: dates of PSA testing in the LPCEDP. The distribution of clinical stages of prostate cancer was analysed in the following age groups: 50–54, 55–59, 60–64, 65–69, 70–75 years. The incidence rate was expressed as cases per 100000 men per year. The logistic regression model was used to assess the effect of the LPCEDP. Results. In 2006–2009, early prostate cancer accounted for 60.9 % of incidence in the study group. The LPCEDP resulted in a sharp rise of the incidence of prostate cancer in 2007, followed by a gradual decline. Major changes in stage II and III tumou